Sulfinpyrazone 是一种口服有效的尿酸剂，具有抗血栓和血小板抑制作用。它可作用于慢性和间歇性痛风性关节炎。

Sulfinpyrazone is a uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.

Sulfinpyrazone exerts significant electrophysiologic actions under various experimental conditions. It raises the ventricular fibrillation threshold as well as the mid diastolic threshold and prolongs the effective refractory period. In the acutely ischemic heart, it attenuates the effect of coronary occlusion on the ventricular fibrillation threshold but has no effect after reperfusion. A protective influence of the drug is also evident during sympathetic humoral stimulation with norepinephrine. The antifibrillatory effect of sulfinpyrazone is additive to the changes elicited by beta adrenergic blockade with practolol or cardiac membrane stabilization with lidocaine[1].

57-96-5

C23H20N2O3S

404.48

NSC 75925;(+/-)-Sulfinpyrazone;苯磺保泰松;G-28315;Sulfinpyrazone

DMSO:73 mg/mL(180.5 mM)
Ethanol:64 mg/mL (158.23 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years